Clinical Trials Logo

Clinical Trial Summary

The epidemic caused by the new coronavirus appeared in December 2019 and spread rapidly, and it has had a serious impact on the social development and people's lives in the world. On February 11, 2020, the World Health Organization (WHO) named the infectious disease caused by the virus COVID-19. my country classifies it as a Class B infectious disease, and controls it as a Class A infectious disease. In order to effectively respond to the epidemic, on January 23, 2020, Zhejiang Province first launched a first-level response to major public health emergencies across the country. Some patients with new coronary pneumonia, especially critically ill patients, may go to the emergency department first. Emergency medical staff must identify and isolate patients with new coronary pneumonia in a timely manner while ensuring the treatment of critically ill patients. People face greater unknowns and challenges in the anti-epidemic work. this research Participating in the prevention and control of the new crown pneumonia epidemic through investigations in the emergency department of Zhejiang Province Related conditions, to further improve the hospital's emergency medical service capabilities for reference.


Clinical Trial Description

References: 1. Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506. DOI:10.1016/s0140-6736(20)30183-5. 2. Zhu N, Zhang DY, Wang WL, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8): 727- 733. DOI:10.1056/nejmoa2001017. 3. Gupta M, Abdelmaksoud A, Jafferany M, et al. COVID-19 and economy[J]. Dermatol Ther, 2020: e13329. DOI:10.1111/dth.13329. 4. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome- related coronavirus: classifying 2019-nCoV and naming it SARS- CoV-2 [J]. Nat Microbiol, 2020, 5(4):536-544. DOI:10.1038/s41564- 020-0695-z. 5. Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges[J]. Int J Antimicrob Agents, 2020, 55(3): 105924. DOI:10.1016/j.ijantimicag.2020.105924. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04915001
Study type Observational
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact
Status Completed
Phase
Start date March 9, 2020
Completion date March 30, 2020

See also
  Status Clinical Trial Phase
Suspended NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Completed NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Completed NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05286255 - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Phase 1
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Completed NCT06113432 - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study N/A
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Completed NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting NCT05047016 - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY N/A
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Recruiting NCT06113757 - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease N/A
Completed NCT05504655 - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Completed NCT05065879 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes Phase 4
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Suspended NCT04901689 - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation Phase 3